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Abstract
Blood pressure is critically controlled by angiotensins1, vasopressor peptides specifically released
by the enzyme renin from the tail of angiotensinogen, a non-inhibitory member of the serpin
family of protease inhibitors2,3. Although angiotensinogen has long been regarded as a passive
substrate, the crystal structures solved here to 2.1Å resolution show that the angiotensin cleavage-
site is inaccessibly buried in its amino-terminal tail. The conformational rearrangement that makes
this site accessible for proteolysis is revealed in a 4.4Å structure of the complex of human
angiotensinogen with renin. The co-ordinated changes involved are seen to be critically linked by
a conserved but labile disulphide bridge. We show that the reduced unbridged form of
angiotensinogen is present in the circulation in a near 40:60 ratio with the oxidised sulphydryl-
bridged form, which preferentially interacts with receptor-bound renin. We propose that this
redox-responsive transition of angiotensinogen to a form that will more effectively release
angiotensin at a cellular level contributes to the modulation of blood pressure. Specifically, we
demonstrate the oxidative switch of angiotensinogen to its more active sulphydryl-bridged form in
the maternal circulation in pre-eclampsia - the hypertensive crisis of pregnancy that threatens the
health and survival of both mother and child.
The octapeptide angiotensin II that constricts arterial blood vessels is released from a
precursor decapeptide, angiotensin I, by the angiotensin converting enzyme ACE. Although
studies of hypertension and its therapy have focused on ACE and its inhibitors the initiating
and rate-limiting step in the angiotensin pathway is the preceding release of angiotensin I, by
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the enzyme renin, from the amino-terminus of the much larger protein, angiotensinogen1,4
(Fig 1a). Previous attempts to determine the structure of plasma angiotensinogen were
frustrated by its heterogeneity, and in order to obtain diffraction-quality crystals
recombinant non-glycosylated angiotensinogens from mouse, rat and human were expressed
in Escherichia coli. Subsequent crystallisation and X-ray diffraction yielded datasets that
were solved as detailed in Methods. The mouse structures were determined at higher
resolution (2.3, 2.1, 2.95Å) but the general features are preserved in the 3.15Å rat and 3.3Å
human structures (as shown separately and with statistics in Figure 2 and Table 1 of the
Supplementary information). With the exception of the exposed and hence mobile reactive
centre loop (residues 408-425), the overall results show the complete fold of the human
molecule including the full amino-terminal extension with the renin cleavage site (Fig 1a).
Although angiotensinogen has only 22% sequence identity to its closest relatives amongst
other serpins3, it substantially retains the typical serpin fold (Supplementary Fig. 2). Of
special interest, the structure shows that Met235, the common polymorphism of which has
been linked to hypertension, has a freely extended side-chain and is situated on an external
peptide loop (hF-s3A) distant from the main functional sites on the molecule. This
strengthens previous deductions5,6 that the predisposition to hypertension results from the
small increase in concentration of the polymorphic angiotensinogen rather than a change in
its function. The 63-residue amino-terminal tail of angiotensinogen is seen as an ordered
superstructure, anchored by two new helices, and with the renin-cleavage site, Leu10-Val11
in humans, held in an inaccessibly buried position. The change in fold allowing access to the
buried cleavage site became apparent with the solution of the structure of the complex of
angiotensinogen and renin. Crystals of the initiating complex formed by human
angiotensinogen with recombinantly inactivated human renin (Asp292Ala) gave X-ray
diffraction to 4.4Å resolution. The structure was solved by molecular replacement, as
detailed in Methods. Although at low resolution, the structure of the complex clearly shows
the mode of binding of renin and the associated localised changes in fold (Fig 1b,
Supplementary Fig 3). In addition to the predicted7,8 intimate interaction between the N-
terminal substrate (angiotensin I) region of angiotensinogen and the active site cleft of renin
there is a substantial contact surface of 670Å2 between the bodies of the two proteins,
primarily hydrophobic in nature. Helix A of angiotensinogen lies across the active site cleft
of renin, and helix C and the CD-loop contact the N-terminal lobe of renin. The body of
angiotensinogen substantially retains its fold except for a displacement of the CD-loop,
which is enlarged and conserved in the angiotensinogens and would otherwise sterically
block the binding of renin. The 10Å shift of this CD loop is accompanied by a 10-20Å
extension and movement of the N-terminal substrate peptide of angiotensinogen into the
active site cleft of renin with, as clearly seen in the structure-video in Supplementary, the
two concerted movements being linked by a disulphide bridge.
The functional significance of this Cys18-138 bridge linking the angiotensin-containing tail
of angiotensinogen to the body of the molecule had been indicated in the earlier biochemical
studies in our group of Streatfeild-James and Coughlin9. Human angiotensinogen contains
four cysteines but those forming the Cys18-138 linkage are the only two conserved in all
species9,10. We now show (Fig 2a) that this disulphide linkage is labile, with a redox
titration of isolated angiotensinogen indicating a reduction potential for this dithiol/
disulphide equilibrium of −230mV at 25°C, pH 7 (see Supplementary Fig 4). That reduction
does result in the breaking of the 18-138 bridge was confirmed in the crystal structure of
reduced mouse angiotensinogen, with the likely structural and hence functional
consequences being indicated by a change of thermal stability, from 62.6°C for the
constrained oxidised-form to 57°C for the relaxed reduced-form (Supplementary Fig. 5).
Angiotensinogen is predictably secreted in the oxidised bridged form after passing through
the endoplasmic reticulum but will then be reduced by interaction with selective thiol-
reductant systems in the plasma. The presence of the reduced as well as oxidised forms of
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angiotensinogen in the plasma is shown in Fig 2b, with a remarkably consistent reduced-to-
oxidised proportion, near 40:60 independent of gender or age, shown in Fig 4a. Although
this is a stable ratio in the plasma pool the redox poise of the transition will predictably
allow the reversible switch from the oxidised to reduced form in focal tissues or vascular
beds.
The critical interactions of renin and angiotensinogen, with respect to the control of blood
pressure, are now believed to occur in the renal tubules and tissue11. At these sites a third
component, the cell-surface prorenin receptor, binds renin to give a considerable
enhancement of its catalytic cleavage of angiotensinogen12. To assess the functional
consequences of the oxidative transition, fully-glycosylated human angiotensinogen, human
renin and human prorenin receptor were recombinantly expressed and isolated. Incubation
of the reduced and oxidised forms of angiotensinogen with renin (Fig 3a,b) shows that the
prorenin receptor whilst having little effect on the reduced form gives a 4-fold increase in
the renin-binding affinity (Km) of the oxidised form, with a consequent 4-fold increase in
the catalytic release of angiotensin. This preferential binding and activation of the oxidised
form of angiotensinogen by the prorenin receptor will particularly occur on cell surfaces,
thus allowing a redox-sensitive and focal modulation of angiotensin release in specific
tissues. Although we demonstrate here the direct effects of the Cys18-138 reduction on the
substrate activity of angiotensinogen, the subsequent ligand-modification of reduced
disulphides is now also known to be widely involved in the modulation of activity in other
proteins13. The potential for such modifications is pertinently14 illustrated with a known
hypotensive agent, nitric oxide. As shown in Fig 3c, incubation of reduced angiotensinogen
with the S-nitrosothiol donor SNAP15,16 leads to the stoichiometric loss of the 18 and 138
thiols, confirming the potential nitrosylation and hence blockage of both cysteines. Taken
together with the structural evidence, these findings of the consequences of the redox
transition of angiotensinogen strongly indicate an as yet unrecognized modulatory
mechanism at the commencement of the principal pathway controlling vasoconstriction.
Previous indications of a redox-sensitive contribution to the control of blood pressure came
from observations of the association of oxidative stress with the onset of episodic
hypertension17,18. Our suspicion that this could result from the oxidative conversion of
angiotensinogen to its more active bridged form was difficult to confirm, as the critical
release of angiotensins is likely to occur focally in renal tissue rather than in the plasma
pool. A more overt occurrence however is the oxidative stress arising from placental
dysfunction14,19. This underlies20,21 the hypertension that commonly complicates
pregnancy and progresses in a quoted 2-7% of all pregnancies to the development of pre-
eclampsia, a leading cause of perinatal and maternal mortality and morbidity in the
developed world22. To determine, as Proof of Principle, if oxidative changes occurred in
angiotensinogen in pre-eclampsia, samples were examined from a previous study of pre-
eclamptic women23. 24 EDTA plasma samples, stored at −80°C, 12 from women with
strictly defined pre-eclampsia and 12 from gestation matched normotensive controls, were
referred for analysis with a blinded coding. The proportion of reduced to oxidised
angiotensinogen in each sample was then assessed by electrophoresis with Western blotting
and the gels compared with the control series in Fig 4a. Visual examination of the 24
maternal samples (Fig 4b) clearly indicated the presence of samples with a decreased
proportion of reduced to oxidised angiotensinogen allowing the ready recognition of 8 of the
12 pre-eclamptic plasmas prior to the breaking of the code. Unequivocal evidence of the
occurrence of the oxidative transition in pre-eclampsia came from the samples with
strikingly obvious decreases in reduced angiotensinogen, as asterisked in Fig 4b, all of
which were revealed to be from pre-eclamptics (see also Supplementary Fig. 6). Subsequent
quantitative measurements (Fig 4c) confirm the visual observations from the gel and also the
findings in studies of other plasma markers23,24 of an overlapping range of oxidative
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changes in pregnancy plasma - from mild in normotensives to severe in pre-eclampsia.
These changes in the plasma pool will be much more marked in the tissues. The more
effective cleavage of the oxidised form of angiotensinogen by cell-bound renin in these
tissues thus provides a contributory causative link between the oxidative changes in
pregnancy and the onset of the hypertension that is a defining feature of pre-eclampsia.
In conclusion, a central message from our findings is that the release of angiotensin requires
a change in conformation in angiotensinogen to allow the access, as well as complementary
binding of renin. At the focus of this change is a labile disulphide bridge that readily
undergoes a transition to a more active oxidised-form and demonstrably so in pre-eclampsia,
the serious hypertensive complication of pregnancy. Evidence that the 4-fold change in
activity that occurs on oxidation is a sufficient cause of pre-eclamptic hypertension, comes
from a fortuitous experiment of nature. A mutation at the renin cleavage site in
angiotensinogen, Leu10Phe, has been previously detected in five heterozygotes, each
identified because of an association with hypertension and specifically with hypertension in
pregnancy. Investigation of the index case of a 17-year-old woman with pre-eclampsia25
showed that the mutation resulted in an increased catalytic efficiency of cleavage of the
angiotensinogen by renin, comparable to the change observed here with the transition of
angiotensinogen from the reduced to oxidised form. Thus there is now a clear chain of
evidence linking the oxidative changes in the placenta with the hypertension in pregnancy
that leads on to the development of pre-eclampsia. The findings here will reinforce efforts to
develop anti-oxidant therapies for pre-eclampsia26 and will also open a means of monitoring
the progress and management of the disorder. In a broader context we draw attention to the
hitherto neglected contribution of angiotensinogen to the multifactorial processes that
modulate blood pressure in man.
Methods Summary
Crystals of angiotensinogen and the complex of human angiotensinogen with de-
glycosylated renin-Asp292Ala were grown at room temperature under conditions listed in
Supplementary Table 1. Datasets were collected at 100K at the Daresbury and Diamond
synchrotron light sources and processed with the CCP4 program suite. The structures of
human, rat and mouse angiotensinogen were solved by molecular replacement in Phaser27,
using an ensemble of distantly related serpins as the search model with additional phase
information obtained from a GdCl3 derivative of human angitensinogen. The structure of the
complex with renin was solved by molecular replacement using renin from PDB entry
2BKS28 and its peptide complex from PDB entry 1SMR7. The structures were completed by
refinement in Refmac529 and rebuilding in coot30. Further details related to crystal
structures and refinement, recombinant expression, thiol titration and nitrosylation and the
assessment of sulphydryl blockage and oxidation, the determination of redox potentials,
renin kinetics and the demonstration of reduced and oxidised forms of angiotensinogen, are
given in Methods.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig 1. Angiotensinogen and its complex with renin
a. Stereo image of human angiotensinogen: serpin template in grey and helix A in purple
with the A-sheet in brown, the unresolved reactive loop in red, and in dark purple the CD
loop containing Cys 138. The amino-tail is in blue with the new helix A1 and a second helix
A2 containing Cys18 (linked in brown to Cys 138); the terminal angiotensin I segment is in
green with the renin-cleavage site shown as green and blue balls. The sequence below (same
colour coding) also indicates the subsequent cleavage by angiotensin converting enzyme
(ACE) releasing the octapeptide angiotensin II. b. the initiating complex formed by
angiotensinogen with inactivated (Asp292Ala) renin (left), and on right superimposed on the
unreacted form (brown) showing the displacement of the CD loop and the movement of the
aminoterminal peptide (visible to Cys 18), into the active cleft of renin (see also
Supplementary Fig 3).
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Fig 2. Reduced angiotensinogen in plasma
a. Ready reduction of the 18-138 disulphide is seen in the native PAGE of recombinant
human angiotensinogen incubated at 23°C for 10 hours with glutathione disulphide (GSSG,
0.1mM) and glutathione (GSH, 0-20mM) and subsequent blockage with iodoacetate (faster
moving band). b. Western blot SDS-PAGE of plasma exposed to N-ethylmaleimide (NEM)
and its high molecular weight polyethylene-glycol adduct (mPEG5K). Blockage of the free
SH groups at Cys232 and 308 with NEM and subsequent reduction with TCEP of the
18-138 bridge and incubation with mPEG5K (lane 3) reveals 2 SH. With fresh unreduced
plasma, incubation with mPEG5K (lane 5) reveals the presence of the two angiotensinogen
forms - oxidised with 2 available SH groups and reduced with 4 SH, giving the consistent
proportions of the two forms in human plasma seen in Fig 4a.
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Fig 3. Kinetics and nitrosylation
a. Reactions of human renin and fully-glycosylated angiotensinogen (oxidised and reduced,
oxi & red) in the presence or absence of prorenin receptor (PRR) with angiotensin I
concentration (after 200-fold dilution) measured by an EIA kit, with in b. the detailed
kinetic parameters. c. The time course of modification of the 18-138 thiols of reduced
angiotensinogen on incubation at 37°C with the S-nitrosothiol donor SNAP, showing the
ready blocking and conversion of the two thiols to S-nitrosothiols. Values are averages of
three independent measurements (mean± SD, n=3).
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Fig 4. Reduced and oxidised plasma angiotensinogen in pregnancy
Western blot SDS-PAGE of plasma exposed to N-ethylmaleimide-polyethylene-glycol
adduct (mPEG). a. Plasma samples from adult controls show remarkably constant 40:60
proportions of the two forms, as do cord (venous umbilical) plasmas from healthy newborns
- taken and stored with the maternal plasmas. R is reduced plasma treated with mPEG. b.
Maternal plasma samples from pre-eclamptics and matched normotensive controls, as
sequentially referred with blinded coding. The recognisably lower proportion of reduced
angiotensinogen in pre-eclamptic plasmas was confirmed on breaking of the coding
(normotensives black numerals, pre-eclamptics red, asterisked four samples self-evidently
below the mean in c.). c. Percentages of the reduced-form in pre-eclamptics (blue), mean 32
± 6 %; and matched normotensive controls (black), mean 40 ± 5 % (means ± SD, n=12, P =
0.004 by Student’s t test). See also Supplementary Fig 6.
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